About | Free Trial

Last Update

2016-03-11T00:00:00.000Z

This profile was last updated on . .

Is this you? Claim your profile.

Wrong Rhett Schiffman?

Dr. Rhett Schiffman M. MD

Associate Clinical Professor of Ophthalmology

University of California , Irvine

HQ Phone: (714) 456-8200

University of California , Irvine

101 The City Drive Bldg. 23; Route 81

Orange, California 92868

United States

Company Description

About the University of California, Irvine: Currently celebrating its 50th anniversary, UCI is the youngest member of the prestigious Association of American Universities. The campus has produced three Nobel laureates and is known for its academic achieve... more

Find other employees at this company (15,458)

Background Information

Employment History

Chief Medical Officer and Executive Vice President Research and Development
Envisia Therapeutics Inc

Vice President of Global Drug Development and Therapeutic Area Head of Ophthalmology
Allergan , Inc.

Chief Medical Officer
Neurotech S.A

Affiliations

Board Member
GRFS LLC

Board Member
Glaucoma Research Foundation

Education

B.S.
Bioengineering
Columbia University

BS
Bioengineering
Columbia University , School of Engineering and Applied Sciences

M.D.

University of Juarez , Mexico

MS

Master's degrees
Clinical Research Design and Statistical Analysis and in Health Services Administration
University of Michigan

Web References (82 Total References)


MANAGEMENT | Envisia

www.envisiatherapeutics.com [cached]

Rhett M. Schiffman, M.D.

Chief Medical Officer & Executive Vice President, Research & Development
Dr. Rhett Schiffman is Senior Vice President of Development and Chief Medical Officer at Envisia. Previously, Dr. Schiffman was the Chief Medical Officer at Neurotech Pharmaceuticals where he led the company's NT-503 program through phase 1/2 clinical trials. Prior to Neurotech, he was Vice President of Global Drug Development and Therapeutic Area Head of Ophthalmology at Allergan where he played a key role in the global development and approval of many successful products including Restasis®, Combigan®, Lumigan®, Acuvail®/Acular®. Zymaxid®/Zymar®, as well as Lumigan® and Ganfort® unit dose products. Dr. Schiffman received his B.S. in Bioengineering from Columbia University and his M.D. from the University of Juarez, Mexico. He also received Master's degrees from the University of Michigan in Clinical Research Design and Statistical Analysis and in Health Services Administration. He completed residencies in both Internal Medicine and Ophthalmology at Henry Ford Hospital in Michigan and is Board Certified in both specialties and completed a Uveitis fellowship at the National Eye Institute at the National Institutes of Health. He has served on the Board of Directors of the Glaucoma Research Foundation and is Associate Clinical Professor of Ophthalmology at the University of California at Irvine where he sees patients and teaches residents.


Executive Team & Board Of Directors | Neurotech Pharmaceuticals

www.neurotechusa.com [cached]

Chief Medical Officer Rhett Schiffman

...
Rhett Schiffman, M.D., M.S., M.H.SA
Chief Medical Officer
Dr. Schiffman joined Neurotech as CMO in September 2013. Rhett Schiffman was most recently Vice President of Global Drug Development and Therapeutic Area Head of Ophthalmology at Allergan, where since 2001 he was instrumental in the global development and approval of many of ophthalmology's most successful products including Restasis®, Combigan®, Lumigan®, Acuvail® and Acular®, Zymaxid® and Zymar® and most recently, the Lumigan® and Ganfort® unit dose products. He also currently serves on the Board of Directors of the Glaucoma Research Foundation and is Associate Clinical Professor of Ophthalmology at the University of California at Irvine. Dr. Schiffman received his B.S. in Bioengineering from Columbia University, School of Engineering and Applied Sciences and his M.D. from the University of Juarez, Mexico. He also received Master's degrees from the University of Michigan in Clinical Research Design and Statistical Analysis and in Health Services Administration. He completed residencies in both Internal Medicine and Ophthalmology at Henry Ford Hospital, is Board Certified in both and completed a Uveitis fellowship at the National Eye Institute at the National Institutes of Health.


Rhett M. Schiffman, MD, MS, MHSA | Glaucoma Research Foundation

www.glaucoma.org [cached]

Rhett M. Schiffman, MD, MS, MHSA

...
Dr. Rhett Schiffman is Vice President of Global Drug Development and Therapeutic Area Head of Ophthalmology at Allergan, Inc.
Dr. Schiffman received his BS in Bioengineering from Columbia University, School of Engineering and Applied Sciences and his MD from the University of Juarez, Mexico. He completed a residency in Internal Medicine at Henry Ford Hospital and is Board Certified.
While a senior staff physician in the Department of Internal Medicine at Henry Ford Hospital, he completed a Master's Degree in Clinical Research Design and Statistical Analysis at the University of Michigan's School of Public Health. He was a staff scientist in the Center for Clinical Effectiveness and the Director of General Internal Medicine Research concentrating on decision analysis, clinical policy assessment and medical informatics.
Dr. Schiffman then completed a residency in Ophthalmology and received Board Certification. He also completed a Fellowship in Uveitis and Ocular Immunology at the National Eye Institute of the National Institutes of Health. He returned to Henry Ford Hospital as the Director of Uveitis Services and the Director of Clinical Research where he was Principal Investigator of numerous NIH and Industry funded studies and authored numerous articles and book chapters. He also received a Master's Degree in Health Services Adminstration from the University of Michigan.
Dr. Schiffman joined Allergan in 2001 and had responsibility for the approval of numerous ophthalmic medications including RESTASIS™, ELESTAT™, ZYMAR™, ZYMAXID™, ACULAR LS™, ACUVAIL™, COMBIGAN™ and LUMIGAN 0.01%™.
He continues to see patients and teach residents at the University of California at Irvine where he is Associate Clinical Professor of Ophthalmology. Dr. Schiffman joined the Glaucoma Research Foundation Board of Directors in 2010.


Rhett M. Schiffman, MD, MS, MHSA | Glaucoma Research Foundation

www.glaucoma.org [cached]

Rhett M. Schiffman, MD, MS, MHSA

...
Rhett Schiffman MD
Dr. Rhett Schiffman is Vice President of Global Drug Development and Therapeutic Area Head of Ophthalmology at Allergan, Inc.
Dr. Schiffman received his BS in Bioengineering from Columbia University, School of Engineering and Applied Sciences and his MD from the University of Juarez, Mexico. He completed a residency in Internal Medicine at Henry Ford Hospital and is Board Certified.
While a senior staff physician in the Department of Internal Medicine at Henry Ford Hospital, he completed a Master's Degree in Clinical Research Design and Statistical Analysis at the University of Michigan's School of Public Health. He was a staff scientist in the Center for Clinical Effectiveness and the Director of General Internal Medicine Research concentrating on decision analysis, clinical policy assessment and medical informatics.
Dr. Schiffman then completed a residency in Ophthalmology and received Board Certification. He also completed a Fellowship in Uveitis and Ocular Immunology at the National Eye Institute of the National Institutes of Health. He returned to Henry Ford Hospital as the Director of Uveitis Services and the Director of Clinical Research where he was Principal Investigator of numerous NIH and Industry funded studies and authored numerous articles and book chapters. He also received a Master's Degree in Health Services Adminstration from the University of Michigan.
Dr. Schiffman joined Allergan in 2001 and had responsibility for the approval of numerous ophthalmic medications including RESTASIS™, ELESTAT™, ZYMAR™, ZYMAXID™, ACULAR LS™, ACUVAIL™, COMBIGAN™ and LUMIGAN 0.01%™.
He continues to see patients and teach residents at the University of California at Irvine where he is Associate Clinical Professor of Ophthalmology. Dr. Schiffman joined the Glaucoma Research Foundation Board of Directors in 2010.


SCHIFFMAN OF ...

www.revoptom.com [cached]

SCHIFFMAN OF ALLERGAN JOINS GRF'S BOARD OF DIRECTORS. Rhett M. Schiffman, MD, MS, MHSA, Allergan, Inc. 's Vice President of Global Drug Development and Therapeutic Area Head of Ophthalmology, has joined the Board of Directors of the Glaucoma Research Foundation (GRF) in San Francisco. In addition to his work for Allergan, Dr. Schiffman continues to see patients and teach residents at the University of California at Irvine, where he is an Associate Clinical Professor of Ophthalmology.

Similar Profiles

Other People with this Name

Other people with the name Schiffman

Jared Schiffman
Potion

Robert Schiffman
Anne Arundel County Literacy Council

Francine Schiffman
Eastern State Penitentiary

Jill Schiffman
Dartmouth College

Penina Schiffman
ProMUNers

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory